A Trump administration push to relax two health-care anti-corruption laws is raising two fundamental questions about industry oversight: How much government monitoring is too much? And will “too much” nullify the expected benefit of the changes?
Without the tougher oversight, proposed new value-based care arrangements that would be permitted under the revised rules could be susceptible to fraud, according to the National Health Care Anti-Fraud Association. But industry officials, eager to modernize the laws, say those concerns are overstated.
The association’s warning reflects the angst among consumer advocates and watchdog groups over the administration’s plans to overhaul the federal anti-kickback ...